Trial Profile

Expanded Access Treatment Protocol With Dichloroacetate Sodium for Patients With Pyruvate Dehydrogenase Complex Deficiency

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 02 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sodium dichloroacetate (Primary)
Indications Pyruvate dehydrogenase complex deficiency disease
Focus Expanded access; Therapeutic Use
Sponsors Saol Therapeutics

Most Recent Events

19 Jun 2025 According to a Saol Therapeutics media release, for Pyruvate Dehydrogenase Complex Deficiency (PDCD) patients who did not participate in the clinical trial, Saol is now conducting an expanded access program (EAP) for eligible PDCD patients.
08 May 2025 Status changed from suspended to recruiting.
22 Apr 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com